Chemoprevention of Oral Premalignant Lesions
Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030-3805
- Pfizer Investigational Site
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Pfizer Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Pfizer Investigational Site
-
-
New York
-
New York, New York, United States
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98195-6607
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 8mm oral premalignant lesion that has not been biopsied in the past 6 months
Exclusion Criteria:
- Taking >100mg daily dose of NSAIDS (Non-steroidal anti-inflammatory drugs)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
To evaluate the efficacy of celecoxib in subjects with Early or Advanced oral premalignant lesion (OPL)
|
|
by both clinical response (reduction in size of all lesions,
|
|
prevention of growth in the index lesion and of any new lesions)
|
|
and histological response (change in histological grade).
|
|
To evaluate the safety of chronic multiple dosing of celecoxib in this patient population.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
To evaluate the treatment effects in modulating the expression of genomic and proliferative markers after 12 weeks of treatment with study drug, followed by 12 weeks off study drug.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Precancerous Conditions
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
Other Study ID Numbers
- NQ4-00-02-011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.